Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Docetaxel and Degarelix in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer

Trial Status: closed to accrual

This phase II trial studies how well docetaxel and degarelix work in treating patients with newly diagnosed prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of tumor cells. Hormone therapy using degarelix may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells. Giving docetaxel and degarelix may work better in treating patients with prostate cancer.